News
Osteoporosis & Bone HealthJAMA Internal Medicine

How Long Until Bisphosphonates Work? Meta-Analysis Quantifies Time to Fracture Prevention

November 8, 2023

A JAMA Internal Medicine meta-analysis of 10 RCTs found that bisphosphonates need about 12 months to prevent a nonvertebral fracture and 20 months for a hip fracture.

Read the original article at JAMA Internal Medicine

Kairos™'s Take

Kairos™'s perspective on this story

A 2021 meta-analysis published in JAMA Internal Medicine pooled data from 10 randomized clinical trials involving 23,384 postmenopausal women with osteoporosis to answer a practical question: how long does bisphosphonate therapy need to continue before it actually prevents fractures? The answer was more specific than previous estimates. To prevent one nonvertebral fracture per 100 women treated, the median time to benefit was 12.4 months. To prevent one hip fracture, it was 20.3 months. For vertebral fractures, the benefit appeared even sooner.

This data is clinically important because it helps set realistic expectations. Bisphosphonates are the most widely prescribed class of osteoporosis medication, yet adherence is notoriously poor — studies consistently show that fewer than half of patients continue therapy beyond one year. If patients and providers understand that the meaningful protection window begins around the 12-month mark, persistence with treatment becomes a more informed decision.

Why This Matters for Midlife Health

For women diagnosed with osteoporosis during or after the menopausal transition, starting treatment is only the first step. The real benefit depends on sticking with it long enough for the medication to do its work. This meta-analysis puts numbers to that timeline, making it possible to have concrete conversations with a provider about what to expect and when. It also reinforces that early diagnosis matters — the sooner treatment starts, the sooner that 12-to-20-month clock begins.

The Tracking Connection

Treatment adherence is one of the hardest problems in osteoporosis management. Kairos™ gives users the ability to log medications, track follow-up DXA results, and see their bone health timeline in context alongside symptoms and lab values. When you can visualize that you are nine months into a treatment with a known 12-month benefit horizon, the motivation to continue is grounded in data rather than faith. Tracking turns compliance into an informed, trackable outcome.

Ready to start tracking?

Kairos™ tracks, scores, and interprets the symptoms of midlife hormonal change — for both women and men.

Get Started

More from the newsroom

Back to all articles